{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:13:21Z","timestamp":1771485201270,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672280"],"award-info":[{"award-number":["81672280"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016803","name":"Natural Science Foundation of Suzhou Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC), particularly in lung adenocarcinoma, and is associated with poor prognosis. A better understanding of the role of PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in the pleural environment and their relevance to patient survival could facilitate better clinical decision-making.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a cohort study involving NSCLC patients with MPE. The abundance of pleural PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells was measured using flow cytometry. We also assessed the presence of epidermal growth factor receptor (EGFR) mutations and programmed death-ligand 1 (PD-L1) expression in the pleural fluid. The LENT score, a known prognostic tool, was combined with pleural PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell abundance to develop a novel scoring system, the Immuno-LENT score. The model\u2019s performance was validated using the bootstrap method and concordance index (C-index) calculation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found that PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells were present in the pleural fluid of all patients with MPE. Notably, the abundance of these cells was influenced by EGFR mutations, while PD-L1 expression had little effect. Patients with a higher abundance of pleural PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells also exhibited higher LENT scores, correlating with poorer survival. The Immuno-LENT score, incorporating both the LENT score and pleural PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell abundance, was found to be an independent prognostic factor. The model showed strong statistical robustness with a high C-index.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      The combination of pleural PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells with the LENT score offers a more accurate prognostic tool for survival prediction in NSCLC patients with MPE. Our findings suggest that the Immuno-LENT score could guide clinical management and inform therapeutic decisions for these patients, improving patient outcomes by tailoring interventions based on a more comprehensive biomarker profile.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1630590","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:41:39Z","timestamp":1771483299000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating pleural PD-1+CD8+ T cell as a complement variable into LENT score to assess patients with lung adenocarcinoma complicated with MPE"],"prefix":"10.3389","volume":"17","author":[{"given":"Weizhen","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leilei","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuxia","family":"Qu","sequence":"additional","affiliation":[{"name":"Clinical Immunology Laboratory, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2022.04.017","article-title":"Malignant pleural effusion: presentation, diagnosis, and management","volume":"135","author":"Gayen","year":"2022","journal-title":"Am J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.136994","article-title":"Management of a Malignant pleural effusion: British Thoracic Society pleural disease guideline 2010","volume":"65","author":"Roberts","year":"2010","journal-title":"Thorax"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccell.2023.12.010","article-title":"Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment","volume":"42","author":"Hoekstra","year":"2024","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen\u2013specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1554969","article-title":"Making cold Malignant pleural effusions hot: driving novel immunotherapies","volume":"8","author":"Murthy","year":"2019","journal-title":"Oncoimmunology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"6178","DOI":"10.3390\/ijms21176178","article-title":"Characteristics of Malignant pleural effusion resident CD8+ T cells from a heterogeneous collection of tumors","volume":"21","author":"Dhupar","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205285","article-title":"Predicting survival in Malignant pleural effusion: development and validation of the LENT prognostic score","volume":"69","author":"Clive","year":"2014","journal-title":"Thorax."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1631800","article-title":"The role of combination chemo-immunotherapy in advanced non-small cell lung cancer","volume":"19","author":"Rocco","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12935-022-02518-w","article-title":"Prognostic biomarkers of Malignant patients with pleural effusion: a systematic review and meta-analysis","volume":"22","author":"Peng","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112798","article-title":"Diving into the pleural fluid: liquid biopsy for metastatic Malignant pleural effusions","volume":"13","author":"Sorolla","year":"2021","journal-title":"Cancers."},{"key":"B12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12931-025-03288-5","article-title":"Pleural fluid biomarkers to predict response to pleurodesis or indwelling pleural catheter for Malignant pleural effusion: still a long way to go","volume":"26","author":"Fjaellegaard","year":"2025","journal-title":"Respir Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3978\/j.issn.2218-6751.2014.05.01","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future","volume":"4","author":"Chan","year":"2015","journal-title":"Trans Lung Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"PD-1\/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions","volume":"24","author":"Xia","year":"2019","journal-title":"oncologist."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2025-003609","article-title":"Retrospective cohort study of survival length in Malignant pleural effusion between 2015 and 2023","volume":"12","author":"Mounsey","year":"2025","journal-title":"BMJ Open Respir Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.01019-2024","article-title":"External validation of the LENT and PROMISE prognostic scores for Malignant pleural effusion","volume":"11","author":"Mounsey","year":"2025","journal-title":"ERJ Open Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2017.378","article-title":"EGFR mutation status in lung adenocarcinoma-associated Malignant pleural effusion and efficacy of EGFR tyrosine kinase inhibitors","volume":"50","author":"Yang","year":"2018","journal-title":"Cancer Res Treat"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/0300060514539273","article-title":"Frequency of EGFR mutations in lung adenocarcinoma with Malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation","volume":"42","author":"Zou","year":"2014","journal-title":"J Int Med Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1630590\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:41:41Z","timestamp":1771483301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1630590\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2026.1630590"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1630590","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"article-number":"1630590"}}